


499 F.3d 1293
United States Court of Appeals,
Federal Circuit.
AVENTIS PHARMA DEUTSCHLAND GmbH, Plaintiff-Cross Appellant,
and
King Pharmaceuticals, Inc., Plaintiff-Cross Appellant,
v.
LUPIN, LTD. and Lupin Pharmaceuticals, Inc., Defendants-Appellants.
Nos. 2006-1530, 2006-1555.
|
Sept. 11, 2007.
Synopsis
Background: Owner of patent brought action against competitor and its agent alleging infringement of patent on pharmaceutical drug that was used to treat high blood pressure. The United States District Court for the Eastern District of Virginia, Robert G. Doumar, Senior District Judge, 2006 WL 2008962,granted judgment for owner. Defendants appealed.
 
Holdings: The Court of Appeals, Linn, Circuit Judge, held that:
 
scientist did not abandon, suppress, or conceal chemical composition, and thus composition had to be considered as part of prior art, and
 
claims of patent for pharmaceutical drug ramipril, which covered 5(S) stereoisomer of ramipril in composition substantially free of other isomers, were invalid over other composition of 5(S) ramipril with its SSSSR stereoisomer.
 
Reversed.
 
